(Q33695775)

28 July 2017

1 reference

title

Novel anticancer drug discovery (English)

1 reference

28 July 2017

1 reference

Buolamwini JK

1

1 reference

28 July 2017

1 August 1999

1 reference

Current Opinion in Chemical Biology

28 July 2017

1 reference

28 July 2017

3

1 reference

28 July 2017

500-509

1 reference

28 July 2017

4

1 reference

Genomics and the discovery of new drug targets

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Requirement of Ras-GTP-Raf Complexes for Activation of Raf-1 by Protein Kinase C

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

The development of monoclonal antibodies for the therapy of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

The structural basis of the activation of Ras by Sos

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Acquisition of high-affinity, SH2-targeted ligands via a spatially focused library

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Pre-clinical development of farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

1 reference

7 January 2021

Protein kinase C: a worthwhile target for anticancer drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Transcription-factor mutations and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

p53, the cellular gatekeeper for growth and division

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Functions of the MDM2 oncoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Bcl-2 and drugs used in the treatment of cancer: new strategies of biotherapy which should not be underestimated

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Urokinase receptor antagonists: novel agents for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Cancer. Proteases--invasion and more.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Adhesion molecules: opportunities for modulation and a paradigm for novel therapeutic approaches in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

RGD peptides induce apoptosis by direct caspase-3 activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Design, synthesis and biological evaluation of nonpeptide integrin antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980073-8

7 January 2021

10.1016/S1367-5931(99)80073-8

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10419854